Clinical Endocrinology · 1995 · 36 citations · 9 references
MedicineEndocrinologyPharmacologyClinical PharmacologyNeuropharmacologyPsychopharmacologyAntidepressant PharmacologyAntidepressant TherapyAutonomic Nervous System PharmacologyNeuroendocrine DisordersMonoamine Oxidase InhibitionMonoamine Oxidase Inhibitor InteractionsMonoamine Oxidase InhibitorsMonoamine Oxidase InvolvementPharmacology Of Sympathomimetic DrugsSympathetic ActivationTricyclic Antidepressant InteractionsTricyclic Antidepressant Therapy
A patient presented with paroxysmal hypertension and typical clinical features of phaeochromocytoma, but with a normal adrenal computed tomographic scan and much higher plasma noradrenaline than adrenaline concentrations. Urinary vanillylmandelic acid concentrations were only moderately elevated. This syndrome probably arose as a consequence of an interaction between the monoamine oxidase inhibitor selegiline, the sympathomimetic agent ephedrine, and a tricyclic antidepressant. The mechanism of the interaction is thought to be related to increased sympathetic release of noradrenaline by ephedrine, inhibition of catabolism by selegiline, and inhibition of reuptake of noradrenaline by the tricyclic. Although newer selective monoamine oxidase inhibitors are considered to be safer than earlier non-selective inhibitors, they can also contribute to drug interactions mimicking phaeochromocytoma.
9
The Pharmacological Basis of Therapeutics
Margene O. Faddis, Alfred G. Gilman · AJN American Journal of Nursing · 1941 · 934 citations
Tyramine pressor sensitivity changes during deprenyl treatment
Trey Sunderland, Edward A. Mueller, Robert M. Cohen et al. · Psychopharmacology · 1985 · 84 citations
Serotonin syndrome caused by a moclobemide-clomipramine interaction.
Olav Spigset, Tom Mjörndal, O Lovheim · BMJ · 1993 · 67 citations · Full text